Auxogyn CEO to Participate in Panel at New York CEO Conference
MENLO PARK, Calif., Nov. 8, 2013 /PRNewswire/ -- Auxogyn, Inc., a leader in reproductive health that provides novel scientific and clinically validated solutions to in vitro fertilization (IVF) clinicians and their patients, today announced that Lissa Goldenstein, Auxogyn's President & Chief Executive Officer, is scheduled to participate in a panel entitled "The Hot IPO Window: Impact on Private Financing Deals" at the New York CEO Conference on November 12, 2013 at 11:30 A.M. EST. The conference will be held at the Apella in New York, NY.
The New York CEO Conference, part of the Boston Biotech Conference series, brings together the most influential leaders in the life sciences and offers a high level of discussion and debate in a collegial atmosphere.
Auxogyn is a leader in reproductive health that provides novel scientific and clinically validated solutions to IVF clinicians and their patients by translating scientific discoveries in early embryo development into clinical tools. The Company's flagship product, the Eeva™ Test, delivers objective information regarding embryo development that IVF clinicians and patients can use to make important treatment decisions. Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, Merck Serono Ventures, SR One and TPG Biotech. For more information visit auxogyn.com and follow us on Twitter @Auxogyn.
About the Eeva™ Test
The Eeva Test provides IVF clinicians with information about the embryo's development potential. Eeva proprietary software automatically analyzes embryo development against scientifically validated cell-division parameters conceived by researchers at Stanford University in the US. With results from the Eeva Test, IVF teams will have morphological assessment and objective information to aid their embryo selection decisions. The Eeva Test was evaluated in a prospective, multi-center, 160-patient prospective multi-center trial with ~1,800 embryos. Results of this study were presented in July 2012 at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting and published by Conaghan et al in Fertility and Sterility, May 2013.
The Eeva Test is currently CE Marked and available for use in the EU and authorized by Health Canada for sale in Canada. The FDA submission is pending and Eeva is not available for sale in the United States. For a full list of clinics in the EU offering the Eeva Test please visit www.eevaivf.com or follow us on Twitter @EevaIVF.
SOURCE Auxogyn, Inc.